Rohto Pharmaceutical Publishes 2026 Annual Report
Bitget2026/10/30 02:25- Rohto Pharmaceutical published its 2026 integrated annual report, reporting record sales and operating profit for fiscal 2025.
- Growth in Southeast Asia and contributions from Eu Yan Sang and MoNo supported overseas expansion.
- The group expects to reach its fiscal 2027 sales target in fiscal 2026, one year ahead of schedule.
- Medical operations remain a growth investment priority, with partnerships advancing regenerative medicine commercialization and contract manufacturing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Arbitrage trading is still profitable, but the "easy win" era may be over! Citi warns of narrowing spread risks
The US foreign exchange trading team at Citigroup expects that although carry trade strategies may find it difficult to replicate the impressive returns of the previous period, they will still continue to offer profit opportunities for investors.
BNB falls below $700
Continue fueling AI expenses! Oracle (ORCL.US) reportedly close to selling $10 billions in stocks at an 11% discount, priced at $116.
It is reported that Oracle is about to sell shares worth 10 billions USD at an 11% discount.
Synthetix Protocol DAO transfers 428,000 stolen SNX
Crypto prices
More
